# Louisiana Prescription Monitoring Program (PMP) Advisory Council

#### MINUTES

A meeting of the Louisiana Prescription Monitoring Program (PMP) Advisory Council was held on **Wednesday**, **February 7**, **2024** at the office of the Louisiana Board of Pharmacy located at 3388 Brentwood Drive in Baton Rouge, Louisiana 70809.

#### 1. Call to Order

Chairman McKay called the meeting to order at approximately 1:33 p.m.

#### 2. Amendments to the Council Roster

Mr. Fontenot reported the amendments to the council roster due to the change in leadership since the last council meeting.

#### 3. Quorum Call

Chairman McKay asked Mr. Fontenot to call the roll of members to establish a quorum.

#### **Members/Designees Present:**

- Marty McKay, Council Chairman, President of the Louisiana Board of Pharmacy
- > Lauren Bailey, Council Vice-Chair, Designee for the President of the Louisiana State Medical Society
- > Patricia Wilton, Designee for the President of the Louisiana State Board of Medical Examiners
- Monique Calmes, APRN, Designee for the President of the Louisiana State Board of Nursing
- > Randal Johnson, President of the Louisiana Independent Pharmacies Association
- > Jacqueline Sanchez, Designee for the President of the Louisiana District Attorneys Association
- Jeff Gaude, Designee for the President of the National Association of Chain Drug Stores
- > Crystal Carter, Designee for the President of the Louisiana Pharmacists Association
- Annette Droddy, Designee for the President of the Louisiana Dental Association
- Chris Melancon, Designee for the Chairman of the Senate Committee on Health and Welfare
- > Traci Perry, Designee for the Secretary of the Louisiana Department of Health
- Lisa Bayhi, APRN, Designee for the President of the Louisiana Association of Nurse Practitioners
- Shelly Esnard, Designee for the President of the Louisiana Academy of Physicians Assistants

#### **Members Absent:**

- > The President of the Louisiana State Board of Dentistry
- > The President of the Louisiana State Board of Optometry Examiners
- The Superintendent of the Louisiana State Police
- The Administrator of the United States Drug Enforcement Administration
- > The Speaker of the Louisiana House of Representatives
- The President of the Louisiana Senate
- > The Chairman of the House Committee on Health and Welfare
- ➤ The President of the Optometry Association of Louisiana
- > The President of the Louisiana Sheriffs' Association
- The President of the Pharmaceutical Research and Manufacturers of America
- > The President of the Louisiana Academy of Medical Psychologists

#### **PMP Advisory Council Meeting Minutes**

February 7, 2024 Page 2

#### **Others Present:**

- M. Joseph Fontenot, Jr., Executive Director, Louisiana Board of Pharmacy
- Carlos M. Finalet, III, General Counsel, Louisiana Board of Pharmacy
- Nerissa I. Montgomery, Administrative Coordinator 3, PMP-Staff, Louisiana Board of Pharmacy
- > Reshmi Ravindranath, Administrative Coordinator 4, PMP-Staff, Louisiana Board of Pharmacy
- > Christina A. Howland, Administrative Coordinator 3, PMP-Staff, Louisiana Board of Pharmacy
- Amy Hammon, Administrative Coordinator 3, PMP-Staff, Louisiana Board of Pharmacy
- Thomas Parrish, Envoc (LA Wallet)
- Alton Ashy, Mobile DMV
- > Sarah Perkins, Breazeale Sachse & Wilson, LLP
- Shelly Dupre, National Association of Chain Drug Stores
- > David Whitehurst, Louisiana Independent Pharmacies Association
- > Don Caffery, Louisiana Independent Pharmacies Association

Mr. Fontenot certified 13 of 24 members were present, constituting a quorum for the conduct of official business.

#### 4. Call for Additional Agenda Items & Adoption of Agenda

No additional agenda items introduced; agenda adopted.

## 5. Consideration of Draft Minutes from Previous Meeting(s): January 11, 2023, and notes from April 12, 2023 and July 12, 2023 meetings

Mr. McKay reminded the members they had received the draft minutes from the council meeting held on January 11, 2023 and the notes from the April 12, 2023 and July 12, 2023 meetings with the meeting notice, as well as copies in their meeting packet. With no objections, he waived the reading of the minutes. With no requests for amendments or corrections, and with no objection, Mr. McKay declared the minutes were approved as presented.

#### 6. Opportunity for Public Comment

Mr. McKay stated the council provides an opportunity for public comment at all meetings, and for each agenda item upon which a vote is to be taken. Prior to each vote, the chair will solicit public comments. He solicited public comments for any topic not already listed on the posted agenda; none were offered.

#### 7. Election of Council Officers: Chair and Vice Chair

The only nomination for the office of Chair was Mr. Marty McKay (LABP). Mr. McKay was elected by acclamation and assumed the office immediately.

The only nomination for the office of Vice Chair was Ms. Lauren Bailey (LSMS). Ms. Bailey was elected by acclamation and assumed the office immediately.

#### 8. Review of Program Operations

Joe Fontenot, Executive Director, presented statistical information regarding the program to the council. (Attachment 1)

#### **PMP Advisory Council Meeting Minutes**

February 7, 2024 Page 3

Mr. Fontenot reviewed the timeline of milestones for the Board's PMP beginning with the PMP program inception in 2009 and ending with the transition to ASAP 4.2B in 2022. Mr. Fontenot explained there continues to be a consistent, downward trend in the number of controlled dangerous substance prescriptions and opioid prescriptions dispensed to Louisiana patients over time. The number of opioid prescriptions has decreased by 36% equating to an overall reduction of greater than 2 million prescriptions since 2016. Comparing the number of controlled substance prescriptions with the number of opioid prescriptions dispensed in CY2023, only 37% of dispensed controlled dangerous substance prescriptions are opioids compared to 47% in CY2016. Mr. Fontenot reviewed the findings from Bamboo Health's Dispensation Dashboard for the 2023 calendar year. Hydrocodone bitartrate/acetaminophen (generic drug name) remains the number one controlled substance prescription dispensed to Louisiana patients since the program

began in 2009. We continue to see a downward trend for Hydrocodone/APAP dispensing by number of prescriptions (39% decrease since 2015) as well as dosage units (47% decrease since 2015) to Louisiana residents over time. The number of therapeutic marijuana recommendations dispensed has significantly increased. There were more than 1.5 million recommendations dispensed to 82,394 patients in 2023. Mr. Fontenot reported that both the AWARxE© and Gateway© searches continue to increase with 80% of searches being done via the PMP integration component, Gateway©.

Mr. Fontenot explained that we continue to send periodic Mandatory Use Non-Compliance Reports based on the State's requirements. Mr. Fontenot reviewed Prescriber Report Cards which were sent to an average of 13,600 eligible prescribers per quarter. Mr. Fontenot explained the significant decrease in Clinical Alerts generated throughout the years since the program started. Mr. Fontenot stated great caution is used in the wording of the Clinical Alerts to emphasize that practitioners use their professional judgement for further review. Mr. Fontenot explained how the PMP staff performs compliance reviews in order to achieve optimum data reporting and quality.

Mr. Fontenot reminded the Council that the LDH - Office of Public Health - Bureau of Community Preparedness grant which used to pay for the Gateway© integration license fees and the NarxCare component expired in September 2023. LDH has agreed to renew the grant, but there will be a significant decrease in funding. The PMP program had to make the difficult decision to discontinue supporting the cost associated with the NarxCare application and choose to provide funding only for the integration component.

#### 9. Opioid Information Manager

Thomas Parrish and Alton Ashy presented the Opioid Information Manager program by Envoc, the creator of the LA Wallet program. Both answered questions from the council members. (Attachment 2).

#### 10. Review of Legislative and Regulatory Activity

Mr. Fontenot discussed the Board of Pharmacy's *Regulatory Project 2023-10* ~ *PMP* which removes naloxone as a drug of concern, clarifies original intent in regards to butalbital as a drug of concern, and addresses record retention of prescription monitoring information.

#### 11. New Agenda Items Added During Meeting

No new agenda items added.

#### 12. Calendar Notes

Mr. McKay stated staff will send notice when the necessity for a meeting arises or the next annual meeting date is finalized.

#### **PMP Advisory Council Meeting Minutes**

February 7, 2024 Page 4

### 13. Adjourn


Having completed the tasks itemized on the posted agenda, with no further business pending before the council and without objection, Chairman McKay adjourned the meeting at approximately 2:43 p.m.


I certify that the foregoing are true and accurate minutes.


Joe Fontenot Executive Director Louisiana Board of Pharmacy


Minutes Prepared by: Reshmi Ravindranath and Nerissa Montgomery, Administrative Coordinators, Louisiana Board of Pharmacy





















CY 2023 Top 10 Controlled Substan Dispensed to Louisiana Patients by <u>Go</u>		1	
Generic Name	Prescriptions	Quantity	Patients
HYDROCODONE BITARTRATE/ACETAMINOPHEN	1,456,812	75,181,210	547,845
DEXTROAMPHETAMINE SULF-SACCHARATE/AMPHETAMINE SULF-ASPARTATE	1,144,113	52,127,742	164,412
ALPRAZOLAM	884,087	45,081,788	167,800
TRAMADOL HCL	586,706	30,679,106	212,998
LISDEXAMFETAMINE DIMESYLATE	548,613	16,675,188	97,837
OXYCODONE HCL/ACETAMINOPHEN	546,632	33,185,377	180,846
ZOLPIDEM TARTRATE	521,935	16,554,219	77,436
CLONAZEPAM	520,979	26,310,010	86,750
PREGABALIN	297,292	22,497,191	62,816
LORAZEPAM	288,332	11,824,781	84,365

#### CY 2023 Top 10 Controlled Substance Prescriptions Dispensed to Louisiana Patients by **Drug Label Name** Label Name Prescriptions Quantity **Patients** HYDROCODONE-ACETAMINOPHEN 10-325 MG TABLET 640,384 45,266,022 150,474 TRAMADOL HCL 50 MG TABLET 572,825 30,199,931 211,395 HYDROCODONE-ACETAMINOPHEN 5-325 MG TABLET 433,959 11,173,752 280,390 ALPRAZOLAM 0.5 MG TABLET 373,006 18,173,556 80,754 **ZOLPIDEM TARTRATE 10 MG TABLET** 365,461 11,659,518 52,220 HYDROCODONE-ACETAMINOPHEN 7.5-325 MG TABLET 359,530 14,537,935 181,561 OXYCODONE-ACETAMINOPHEN 10-325 MG TAB 278,795 63,103 21,273,692 **DEXTROAMP-AMPHETAMIN 30 MG TAB** 40,994 275,944 15,035,355 ALPRAZOLAM 1 MG TABLET 275,456 15,990,801 40,976 **DEXTROAMP-AMPHETAMIN 20 MG TAB** 247,930 13,979,047 46,680










	Number of Providers	Number of	Number of PMP	Number of PMP
	Eligible	Providers with	Requests by	Requests by
	for PMP Access	Active PMP Access	Providers through	Providers through
	(as of 12/31/2023)	Privileges (as of	AWARxE®	Gateway <sup>®</sup>
PMP Healthcare Provider Role		12/31/2023)	During 2023Q4	During 2023Q4
Physician (MD, DO)	13,684	9,552	541,384	6,624,435
Nurse Practitioner (APRN)	5,257	4,178	248,968	620,854
Dentist (DDS)	2,252	1,469	5,801	4,743
Physician Assistant (PA)	1,370	1,082	45,362	74,254
Optometrist (OD)	366	153	2	0
Podiatrist (DPM)	169	120	2,009	0
Medical Psychologist (MP)	99	94	7,579	11,204
Medical Intern/Resident	1,725	1,181	10,249	194,715
Prescriber's Delegate	N/A	3,915	184,187	N/A
Pharmacist (PST)	9,307	5,402	1,269,546	2,119,448
Pharmacist's Delegate	N/A	1,709	117,844	N/A
Totals	34,229	28,855	2,432,931	9,649,653

14



### MANDATORY USE COMPLIANCE

 Louisiana PMP uses the Mandatory Use Module to view a prescriber's compliance with State requirements to query a patient's prescription history before prescribing opioid prescriptions.

#### **Mandatory Use Non Compliance Report**

- · Report sent to LSMBE & LSBN in January, April and December
- Report for October December 2023 for LSBME & LSBN In Process

#### LA R.S. 40, Chapter 4, Part X, §978. Prescriptions

F. (1) A prescriber or his delegate shall access and review the patient's record in the prescription monitoring program established in <u>R.S. 40:1001</u> et seq. prior to initially prescribing any opioid to a patient and shall access the prescription monitoring program and review the patient's record at least every ninety days if the patient's course of treatment continues for more than ninety days. The requirement established in this Subsection shall not apply in the following instances:

(a) The drug is prescribed or administered to a hospice patient or to any other patient who has been diagnosed as terminally ill.

(b) The drug is prescribed or administered for the treatment of cancer-related chronic or intractable pain.

(c) The drug is ordered or administered to a patient being treated in a hospital.

(d) The prescription monitoring program is inaccessible or not functioning properly due to an internal or external electronic issue. However, the prescriber or his delegate shall check the prescription monitoring program once electronic accessibility has been restored and note the cause for the delay in the patient's chart.

(e) No more than a single seven-day supply of the drug is prescribed or administered to a patient.


16

### PRESCRIBER REPORT CARDS


- Louisiana delivers Prescriber Report cards every quarter to all prescribers in reporting period reflecting opioid, sedative, or stimulant medications during the last six (6) months.
- The report metrics include comparing prescribing behavior against peers within the prescriber's healthcare specialty.

#### Reports sent in 2023


- Q1 Reports sent to 13,616 Prescribers
- Q2 Reports sent to 13,639 Prescribers
- Q3 Reports sent to 13,606 Prescribers
- Q4 Reports sent to 13,653 Prescribers





17













# OPIOID INFORMATION MANAGER



An in-pharmacy solution to the substance abuse crisis with real-time prescription pick-up monitoring.

Our nation is facing a substance abuse crisis that has claimed too many lives and continues to destroy families and even whole communities. To help avoid this terrible epidemic, Envoc has created the **Opioid Information Manager (OIM)** app to address the 24-hour delay currently in place with the prescription drug monitoring program (PDMP). After the successful launch of LA Wallet, the nation's first digital driver's license app, Envoc reengineered the innovative digital identification verification system VerifyYou<sup>TM</sup> to develop a real-time prescription pick-up monitoring system.

#### **How it Works**

Opioid Information Manager (OIM) utilizes the universal AAMVA barcode on the back of every state-issued identification credential and the same engine powering LA Wallet that instantly verifies over 335,000 Louisiana residents. The Opioid Information Manager (OIM) system only requires an iPad and Zebra Bluetooth scanner to track real-time prescription pickups in order to prevent an individual from picking up multiple prescriptions and from different locations within a 24-hour period.

#### **Key Benefits**

The Zebra scanner provides pharmacies with a simple yet powerful tool to detect multiple prescription pick-ups in a 24-hour period.



Visual and Audible Confirmation or Disapproval Signals



Optional Pick-up Log



Optional iPad On-screen Image of License Holder



Instant Results



Eliminates 24-hour Tracking Gap



**HIPPA Compliant** 



# OPIOID INFORMATION MANAGER







#### **Opioid Abuse Prevention Overview**

The **Opioid Information Manager (OIM)** offers the advantages of instantaneous verification with a scan of the AAMVA barcode printed on the back of all state-issued licenses and ID cards, as well as digital AAMVA barcodes.

The use of the **Opioid Information Manager (OIM)** can be leveraged to update an opioid distribution database with all prescription purchases by an individual.

A stand-alone station with a dedicated scanner will be provided by the **Opioid Information Manager (OIM)** administrator for real-time verification of prescription eligibility and dispensing.

The proposed implementation of this system will address the issues of multiple prescriptions filled at different locations whether they are duplicated prescriptions or multiple opioid prescriptions from different prescribers (i.e. "doctor shoppers").

#### Contact

oim@envoc.com | (225) 384-5549

#### About Envõc

Envoc is a Custom Software and Design Company that provides custom software solutions for businesses and individuals. When you can't find the software you need off the shelf, we create the software you need to improve and grow your business. Our services range from mobile applications, intranets, portals, content management software, customer-facing websites and web applications, all the way to branding of your company or product. Our in-house team of experts works smartly and efficiently to make your customer-facing site or internal application beautiful and eye-catching, in addition to the stellar team of developers to create the software that, at this point, you've only dreamt about. Learn more at envoc.com